STEP-1
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
Definition
The pivotal phase 3 of semaglutide 2.4 mg weekly against placebo in 1,961 adults with overweight or obesity (Wilding et al., NEJM 2021, PMID 33567185). Mean weight loss 14.9% at 68 weeks. This is the number underneath most semaglutide marketing you will read, including marketing for compounded products that were never in it.
STEP-1 side-effect data investigation →
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.
Other terms under Major trials
Where the evidence lives
- STEP-1 side-effect data investigation
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers